IN2015KN00329A - - Google Patents

Info

Publication number
IN2015KN00329A
IN2015KN00329A IN329KON2015A IN2015KN00329A IN 2015KN00329 A IN2015KN00329 A IN 2015KN00329A IN 329KON2015 A IN329KON2015 A IN 329KON2015A IN 2015KN00329 A IN2015KN00329 A IN 2015KN00329A
Authority
IN
India
Prior art keywords
compositions
diseases
disclosed
methods
encompass
Prior art date
Application number
Other languages
English (en)
Inventor
Christopher K Garcia
Darren L Bates
Ignacio Moraga
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of IN2015KN00329A publication Critical patent/IN2015KN00329A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IN329KON2015 2012-08-09 2013-08-08 IN2015KN00329A (enExample)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261681490P 2012-08-09 2012-08-09
US201261725791P 2012-11-13 2012-11-13
US201361825980P 2013-05-21 2013-05-21
PCT/US2013/054164 WO2014074186A2 (en) 2012-08-09 2013-08-08 Superkines and synthekines: repurposed cytokines with new and enhanced signaling activities

Publications (1)

Publication Number Publication Date
IN2015KN00329A true IN2015KN00329A (enExample) 2015-07-10

Family

ID=50685291

Family Applications (1)

Application Number Title Priority Date Filing Date
IN329KON2015 IN2015KN00329A (enExample) 2012-08-09 2013-08-08

Country Status (6)

Country Link
US (3) US9738696B2 (enExample)
EP (1) EP2882449B1 (enExample)
JP (2) JP6445434B2 (enExample)
CN (2) CN110615835A (enExample)
IN (1) IN2015KN00329A (enExample)
WO (1) WO2014074186A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019531729A (ja) * 2016-09-30 2019-11-07 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 変異体ｉｉｉ型インターフェロン及びシンセカイン
JP2018157812A (ja) * 2017-03-23 2018-10-11 東ソー株式会社 試料中に含まれる細胞の検出方法
KR20190133707A (ko) * 2017-03-31 2019-12-03 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 신테카인 조성물 및 사용방법
MX2020012251A (es) 2018-05-14 2021-04-28 Werewolf Therapeutics Inc Polipeptidos de interleucina-2 activables y metodos de uso de los mismos.
MX2020012252A (es) 2018-05-14 2021-04-28 Werewolf Therapeutics Inc Polipeptidos de interleucina 12 activables y metodos de uso de los mismos.
CA3102097A1 (en) 2018-06-01 2019-12-05 The Board Of Trustees Of The Leland Stanford Junior Unversity Il-13/il-4 superkines: immune cell targeting constructs and methods of use thereof
JP7641912B2 (ja) 2019-04-19 2025-03-07 シナーキン・ファーマ・ベスローテン・フエンノートシャップ Ｉｌ１３を含む融合タンパク質
KR20220023988A (ko) 2019-05-14 2022-03-03 웨어울프 세라퓨틱스, 인크. 분리 모이어티 및 이의 사용 방법
CA3155981A1 (en) 2019-11-14 2021-05-20 William Winston Activatable cytokine polypeptides and methods of use thereof
WO2023230163A1 (en) * 2022-05-24 2023-11-30 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Interleukin 4 and/or interleukin 13-based eye compositions

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2142860A1 (en) 1992-08-21 1994-03-03 Gregorio Aversa Human interleukin-13
US5635599A (en) 1994-04-08 1997-06-03 The United States Of America As Represented By The Department Of Health And Human Services Fusion proteins comprising circularly permuted ligands
DE4423131A1 (de) * 1994-07-01 1996-01-04 Bayer Ag Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4
FR2742156A1 (fr) 1995-12-06 1997-06-13 Sanofi Sa Polypeptide recepteur de l'il-13
US6335426B1 (en) * 1996-06-14 2002-01-01 Bayer Corporation T-cell selective interleukin-4 agonists
US6028176A (en) * 1996-07-19 2000-02-22 Bayer Corporation High-affinity interleukin-4 muteins
US6673602B1 (en) 1999-06-11 2004-01-06 The General Hospital Corporation Herpes simplex virus amplicon vector targeting system and method of using same
US6737511B1 (en) 1999-08-16 2004-05-18 The United States Of America As Represented By The Department Of Health And Human Services Receptor-mediated uptake of an extracellular BCL-xL fusion protein inhibits apoptosis
MXPA02002684A (es) 1999-09-09 2002-07-30 Schering Corp Citocinas de mamifero; reactivos y metodos relacionados.
JP2003511019A (ja) 1999-10-06 2003-03-25 ザ ペン ステート リサーチ ファウンデーション Ｉｌ１３変異体
CA2404763A1 (en) 1999-11-11 2001-05-17 Raj K. Puri Mutated il-13 molecules and their uses
GB0004016D0 (en) 2000-02-22 2000-04-12 Royal Brompton Hospital Biological material and uses thereof
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
DE60142479D1 (de) 2000-08-30 2010-08-12 Penn State Res Found Aminosäureaustauschmutanten von interleukin 13
EP1328260A2 (en) 2000-10-18 2003-07-23 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
US7087224B2 (en) 2000-10-31 2006-08-08 Amgen Inc. Method of treating anemia by administering IL-1ra
EP1402451A4 (en) 2001-06-07 2005-01-05 Wyeth Corp SOLUTION STRUCTURE OF IL-13 AND USE THEREOF
US20040248260A1 (en) 2001-10-26 2004-12-09 Heavner George A. IL-13 mutein proteins, antibodies, compositions, methods and uses
AU2006203850A1 (en) 2005-01-10 2006-07-13 Research Development Foundation Targeted chimeric molecules for cancer therapy
CA2622504A1 (en) 2005-09-09 2008-03-08 Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for inhibiting cell death or enhancing cel proliferation
US20070160658A1 (en) 2005-10-20 2007-07-12 The Penn State Research Foundation Delivery system for diagnostic and therapeutic agents
EP3540054A3 (en) 2006-06-07 2019-10-09 Genzyme Corporation Gene therapy for amyotrophic lateral sclerosis and other spinal cord disorders
WO2008101671A2 (en) 2007-02-19 2008-08-28 Apogenix Gmbh Il-4 fc fusion proteins
CA2697529A1 (en) 2007-08-24 2009-03-05 Regents Of The University Of Minnesota Receptor-targeting reagents
US20110077202A1 (en) 2008-05-16 2011-03-31 Bayer Healthcare Llc Targeted Coagulation Factors and Method of Using the Same
EP2352526A1 (en) 2008-09-19 2011-08-10 Protox Therapeutics Inc. Treating cancer stem cells using targeted cargo proteins
US20100183545A1 (en) 2008-10-14 2010-07-22 The United States Of America, As Represented By The Secretary, Targeted cargo protein combination therapy
JP2010154842A (ja) 2008-12-03 2010-07-15 Koji Kawakami Ｅｇｆｒを標的にした新規抗がんキメラペプチド
US20110023680A1 (en) 2009-07-30 2011-02-03 Kuo-Chung Wang Pcb cutter module with detachable cutters
TWI397428B (zh) 2009-12-29 2013-06-01 Ind Tech Res Inst 標的第四介白素受體之傳輸系統
WO2011106779A1 (en) 2010-02-26 2011-09-01 Aerovance Inc. Use of modified il-4 mutien receptor antagonists to treat dermatitis
JP5734951B2 (ja) 2010-03-03 2015-06-17 シャープ株式会社 表示装置およびその駆動方法、ならびに液晶表示装置
WO2012054929A2 (en) 2010-10-22 2012-04-26 Protox Therapeutics Corp. Use of human serum albumin to decrease antigenicity of therapeutic proteins
WO2012088446A1 (en) 2010-12-22 2012-06-28 Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
WO2012139112A1 (en) 2011-04-08 2012-10-11 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Ubiquitin fusions for improving the efficacy of cytosolic acting targeted toxins
MX347656B (es) 2011-04-08 2017-05-08 Baylor College Medicine Inversion de los efectos del micro-ambiente de tumor utilizando receptores de citocina quimericos.
US9512194B2 (en) 2012-01-27 2016-12-06 The Board Of Trustees Of The Leland Stanford Junior University Modified IL-13 polypeptides
WO2015042705A1 (en) 2013-09-24 2015-04-02 Medicenna Biopharma Inc. Interleukin-4 receptor-binding fusion proteins and uses thereof
US10781242B2 (en) 2013-09-24 2020-09-22 Medicenna Therapeutics Inc. Interleukin-2 fusion proteins and uses thereof
WO2015070210A1 (en) 2013-11-11 2015-05-14 Wake Forest University Health Sciences Epha3 and multi-valent targeting of tumors
CN106459990B (zh) 2014-02-07 2021-06-01 麦克马斯特大学 三功能t细胞抗原偶联物及其制备方法和用途
US20180133252A9 (en) 2014-09-09 2018-05-17 Unum Therapeutics Inc. Chimeric receptors and uses thereof in immune therapy
AU2015317351B2 (en) 2014-09-19 2020-07-02 City Of Hope Costimulatory chimeric antigen receptor T cells targeting IL3Ra2
SG10202103475XA (en) 2014-12-02 2021-05-28 Prospect Chartercare Rwmc Llc Methods and compositons for treating cancer
EA039865B1 (ru) 2016-01-11 2022-03-22 Универзитет Цюрих Иммуностимулирующее гуманизированное моноклональное антитело против интерлейкина-2 человека и слитый белок
WO2018112266A1 (en) 2016-12-14 2018-06-21 The Board Of Trustees Of The Leland Stanford Junior University Il-13 superkine: immune cell targeting constructs and methods of use thereof
WO2019051204A1 (en) 2017-09-08 2019-03-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services SYNERGISTIC COMBINATION OF IL4, INTERFERON GAMMA AND INTERFERON ALPHA RECEPTOR AGENTS FOR USE IN THE TREATMENT OF OVARIAN CANCER
US12274735B2 (en) 2017-10-10 2025-04-15 Medicenna Therapeutics Inc. IL-4-fusion formulations for treatment of central nervous system (CNS) tumors
CN113728232A (zh) 2019-02-07 2021-11-30 梅迪塞纳医疗股份有限公司 作为癌症中的生物标志物的il-4r
WO2021258213A1 (en) 2020-06-24 2021-12-30 Medicenna Therapeutics Inc. Bifunctional superkines and uses thereof

Also Published As

Publication number Publication date
EP2882449A4 (en) 2016-03-09
US20210188932A1 (en) 2021-06-24
CN104619334A (zh) 2015-05-13
US20180016316A1 (en) 2018-01-18
JP6445434B2 (ja) 2018-12-26
JP2018161143A (ja) 2018-10-18
WO2014074186A2 (en) 2014-05-15
EP2882449A2 (en) 2015-06-17
JP2015525574A (ja) 2015-09-07
US12187771B2 (en) 2025-01-07
US10738096B2 (en) 2020-08-11
WO2014074186A3 (en) 2014-06-19
CN110615835A (zh) 2019-12-27
US20160244499A1 (en) 2016-08-25
US9738696B2 (en) 2017-08-22
EP2882449B1 (en) 2019-05-15

Similar Documents

Publication Publication Date Title
IN2015KN00329A (enExample)
CY1123106T1 (el) Αγωγη ανοσοσχετιζομενων και φλεγμονωδων νοσων
MX2013015168A (es) Co-agonista del receptor de glucagon/glp-1.
PH12013502671A1 (en) Glucagon/glp-1 receptor co-agonists
MX2019014009A (es) Metodos mejorados para la elaboracion de terapias celulares adoptivas.
CR20160576A (es) Anticuerpos dirigidos contra cd127
MX2015003140A (es) Formulaciones de enzalutamida.
MX2015001871A (es) Celulas asesinas naturales y usos de las mismas.
UY34617A (es) Composiciones veterinarias orales parasiticidas que comprenden agentes activos de acción sistémica, métodos y usos de las mismas
PH12016500862B1 (en) Autotaxin inhibitor compounds
AU355788S (en) Portable activity monitor
MX2015014438A (es) Metodos de uso de interleucina-10 para tratar enfermedades y trastornos.
MX384095B (es) Uso de dosis bajas de il-2 para tratar trastornos inflamatorios o relacionados con la autoinmunidad.
MX2016008448A (es) Conjugados de var2csa-farmaco.
MX375592B (es) Composiciones y su uso para tratar hemoglobinopatias.
MY156697A (en) Modified tuberculosis antigens
CL2012003745A1 (es) Compuestos derivados de aminopirazoloquinazolinas, como inhibidores frente a la actividad fosforilante del receptor igf-1 localizado en membranas celulares; preparacion farmaceutica que los contiene; y su uso en el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
EP2558124A4 (en) POLYSACCHARID COMPOSITIONS AND METHOD FOR USE THEREOF FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH PRECURSOR CELL MOBILIZATION
PH12016500863A1 (en) Tetracyclic autotaxin inhibitors
CA140003S (en) Mount for log splitting wedge
MX2015003765A (es) Arterivirus.
WO2013109055A3 (ko) 개 유래의 자연살해세포 및 이의 대량 증식방법
MX2018000411A (es) Microorganismos con capacidad de absorcion de luz ampliada y aumento de la actividad fotosintetica.
EP2955776A4 (en) OXYGEN REDUCTION CATALYST, OXYGEN REDUCTION ELECTRODE AND FUEL CELL
ES2673028T3 (es) Reducción selectiva de la actividad perjudicial de genes que contienen repeticiones de trinucleótidos prolongadas